Xeris Biopharma Holdings, Inc.
XERS
$4.46
$0.030.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 222.55M | 203.07M | 187.36M | 181.41M | 171.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 222.55M | 203.07M | 187.36M | 181.41M | 171.36M |
| Cost of Revenue | 39.59M | 36.83M | 34.92M | 29.53M | 29.30M |
| Gross Profit | 182.96M | 166.24M | 152.44M | 151.88M | 142.06M |
| SG&A Expenses | 163.02M | 157.38M | 160.91M | 153.23M | 150.87M |
| Depreciation & Amortization | 10.84M | 10.84M | 10.84M | 10.84M | 10.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 238.94M | 230.62M | 232.53M | 218.60M | 216.33M |
| Operating Income | -16.39M | -27.55M | -45.17M | -37.19M | -44.98M |
| Income Before Tax | -47.65M | -57.10M | -65.62M | -59.08M | -65.34M |
| Income Tax Expenses | -2.58M | -2.27M | -2.50M | 482.00K | -942.00K |
| Earnings from Continuing Operations | -45.08 | -54.84 | -63.11 | -59.56 | -64.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.08M | -54.84M | -63.11M | -59.56M | -64.40M |
| EBIT | -16.39M | -27.55M | -45.17M | -37.19M | -44.98M |
| EBITDA | -4.33M | -15.48M | -33.06M | -25.00M | -32.69M |
| EPS Basic | -0.30 | -0.38 | -0.44 | -0.42 | -0.46 |
| Normalized Basic EPS | -0.18 | -0.23 | -0.30 | -0.27 | -0.30 |
| EPS Diluted | -0.30 | -0.38 | -0.44 | -0.42 | -0.46 |
| Normalized Diluted EPS | -0.18 | -0.23 | -0.30 | -0.27 | -0.30 |
| Average Basic Shares Outstanding | 598.88M | 586.95M | 575.98M | 565.04M | 554.04M |
| Average Diluted Shares Outstanding | 598.88M | 586.95M | 575.98M | 565.04M | 554.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |